CHPA Regulatory & Scientific Conference In Brief
This article was originally published in The Tan Sheet
Executive Summary
OTC monograph finalization may never end, FDA exec suggests; agency official advises coloring inside the monograph lines; OTC adverse event reports fell about 19% in 2011; supplement AER practices can mitigate rising insurance rates.
You may also be interested in...
In Brief
Pernix, SEEK prep new cough med; FDA warns Quadex over herpes reference; NuMe progresses on prebiotic program; Creative Edge Nutrition expands; Reaction Nutrition records lacking; more news In Brief.
In Brief
FDA softens disclaimer for green tea QHC; Formulife/Purus covers spectrum of violations; NAD refers Schick case to FTC; Genomma drops Prestige Brands board bid.
Supplement AER Under-Reporting Marks Tip Of Compliance Iceberg – FDA
FDA’s dietary supplement program chief raised eyebrows at a botanical products conference citing low estimates on rates of compliance with the good manufacturing practices final rule and the new dietary ingredient notification requirements, as well as adverse event reporting.